Methods to treat dysregulated blood glucose disorders
The invention provides methods and compositions for treating dysregulated blood glucose disorders.
1. A method for treating a dysregulated blood glucose disorder in a mammal in need thereof comprising administering an effective amount of D-serine or a pharmaceutically acceptable salt thereof, D-cycloserine or a pharmaceutically acceptable salt thereof, or glycine or a pharmaceutically acceptable salt thereof to the mammal in need thereof.
2. The method of claim 1 , wherein D-serine or a pharmaceutically acceptable salt thereof is administered.
3. The method of claim 1 , wherein D-cycloserine or a pharmaceutically acceptable salt thereof is administered.
4. The method of claim 1 , wherein glycine or a pharmaceutically acceptable salt thereof is administered.
5. The method of claim 1 , wherein the dysregulated blood glucose disorder is hyperglycemia.
6. The method of claim 5 , wherein the hyperglycemia is caused by pancreatitis, pancreatic cancer, hyperthyroidism, Cushing's syndrome, glucagonoma, pheochromocytoma, stress episodes, medication side-effects, pregnancy, insulin resistance or insulin deficiency.
7. The method of claim 5 , wherein the hyperglycemia is caused by insulin resistance.
8. The method of claim 1 , wherein the dysregulated blood glucose disorder is diabetes.
9. The method of claim 1 , further comprising administering insulin to the mammal.
10. The method of claim 9 , wherein the D-serine, D-cycloserine, or glycine, or a pharmaceutically acceptable salt thereof and the insulin are co-administered.
11. The method of claim 1 , further comprising administering a D-amino acid oxidase inhibitor or a pharmaceutically acceptable salt thereof to the mammal.
12. The method of claim 1 , further comprising administering an antidiabetic agent or a pharmaceutically acceptable salt thereof to the mammal.
13. The method of claim 1 , wherein the mammal is a human.
14. A pharmaceutical composition comprising D-serine or a pharmaceutically acceptable salt thereof, D-cycloserine or a pharmaceutically acceptable salt thereof, or glycine or a pharmaceutically acceptable salt thereof, insulin and a pharmaceutically acceptable carrier.
15. The pharmaceutical composition of claim 14 , comprising D-serine or a pharmaceutically acceptable salt thereof, insulin and a pharmaceutically acceptable carrier.
16. The pharmaceutical composition of claim 14 , further comprising a D-amino acid oxidase inhibitor or a pharmaceutically acceptable salt thereof.